CHAPEL HILL, N.C. — Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering.

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company are serving as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.

http://www.prnewswire.com/news-releases/cempra-holdings-llc-files-registration-statement-for-proposed-initial-public-offering-131628393.html

SUNRISE, FL - Bioheart BioheartLatest from The Business JournalsHot LeadsBioheart terminates AnC Bio’s .6M investmentBioheart secures M investmentFollow this company announced a deal to raise $3 million by selling its common stock over the next two years.

The Sunrise-based development stage biotechnology company (OTCBB: BHRT) is working on clinical trials for its MyoCell product, a potential stem cell treatment for heart disease. It did not name the investor who agreed to buy its stock.
(more…)

ATLANTA, GA - A Marietta-based based medical device company that focuses on catheter technologies has raised $2.35 million, according to a Securities and Exchange Commission Securities and Exchange CommissionLatest from The Business JournalsHCA to offer 0 million in notesRBC pays million to SEC in Stifel-Wisconsin flapAmerican Airlines to raise 5 million in debtFollow this company filing.

Atlanta Catheter Therapies Inc. has a portfolio of catheter technologies for the treatment of vascular disease and restenosis.
(more…)

ATLANTA, GA - Creative new drug therapies, advanced medical devices, diagnostics and nanotechnologies from throughout the Southeast will be in the spotlight November 2 and 3 during the 2011 Southeast BIO Investor Forum at the Washington Duke Inn in Durham, N.C.
(more…)

ATLANTA, GA - While deal activity tends to slow in the summer months, the news was generally positive for the Southeast region. Several significant venture rounds were completed, including an eyeball-popping $100M series E for Intrexon Corporation (Blacksburg, VA), the synthetic biology company backed by billionaire Randall Kirk.
(more…)

ATLANTA, GA -GeoVax Labs Inc. GeoVax Labs Inc.Latest from The Business JournalsNew institute focusing on repairing the bodyGeoVax gets .6M IPCAVD grantGeoVax records 1,000 Q2 lossFollow this company’s recent $3.6 million Integrated Preclinical/Clinical AIDS Vaccine Development grant has been boosted to $4.4 million.
(more…)

ATLANTA, GA - Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has secured $13.1 million in a Series D financing.
(more…)

ATLANTA, GA - The U.S. Food and Drug Administration U.S. Food and Drug AdministrationLatest from The Business JournalsAlcon files patent infringement claim against Apotex‘Gray’ drug market preys on hospitals hereFen-phen deadline nearing, Dallas lawyer warnsFollow this company on Friday stamped its approval on Dendreon Corp. Dendreon Corp.Latest from The Business JournalsSeattle Genetics’ new drug price: 8K per patientHines marketing planned Perimeter office towerWhich Seattle-area stocks are down the most?Follow this company’s Atlanta cancer immunotherapy manufacturing facility.
(more…)

ATLANTA, GA - Morrisville, NC-based Furiex Pharmaceuticals Inc. says it has inked a loan agreement for $15 million to support research and development on three of its clinical stage compounds. The lenders are MidCap Financial MidCap FinancialLatest from The Business JournalsHawaii Medical Center files Chapter 11 bankruptcy — againCarepoint acquires ArTex infusion firmAtherotech acquired by Behrman CapitalFollow this company and Silcon Valley Bank.
(more…)

ATLANTA, GA _ BioDelivery Sciences International Inc.BioDelivery Sciences International Inc.Latest from The Business JournalsBDSI poised to file to market drugBDSI lines up M to finance drugFirm claims BDSI infringing on its methodFollow this company said that its drug Onsolis will soon be sold in Canada – a development that could generate up to $30 million in sales milestones for the Raleigh-NC-based company.
(more…)